Cell infusion
After 14 days of cultivation, the proportion of obtained CD4, CD8, and NKT cells was as follows: CD3+: 85–98.3%, with an average of 92.6%; CD3+CD8+: 49.6–81.8%, with an average of 68.2%; CD3+CD4+: 9.7–43.5%, with an average of 22.7%; CD3-CD56+: 1–15%, with an average of 6.0%; and CD3+CD56+(NKT): 3.4–27.4%, with an average of 13.4%. The final cell products in all patients were highly viable (95%) and uncontaminated. After completing quality testing, all qualified immune cells were infused back into the patients. All patients in the CIK group completed at least one cycle of immune cell infusion containing an average of 8.6×10